bioAffinity's CyPath Lung Test Averts Invasive Procedures in High-Risk Patient Case
Event summary
- CyPath Lung test yielded negative result for 71-year-old high-risk patient with multiple pulmonary nodules, avoiding invasive procedures.
- Follow-up CT scan in October 2025 confirmed nodules were benign, validating CyPath Lung's accuracy.
- Test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in clinical studies for detecting lung cancer.
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) under CLIA oversight.
The big picture
The case study underscores the growing role of AI-driven diagnostic tools in precision medicine, particularly for early cancer detection. As healthcare systems face pressure to reduce costs and improve outcomes, noninvasive tests like CyPath Lung could gain traction. The success of such technologies hinges on demonstrating consistent accuracy and integration into existing clinical workflows.
What we're watching
- Clinical Adoption
- How quickly pulmonologists will integrate CyPath Lung into standard diagnostic pathways for high-risk patients.
- Cost Efficiency
- Whether the test's ability to reduce invasive procedures will translate into measurable healthcare cost savings.
- Regulatory Landscape
- The pace at which LDT oversight by CMS may evolve and impact bioAffinity's operational flexibility.
Related topics